Milnacipran has been shown equally effective as imipramine for the treatment of major depression as well as having a far superior tolerance.
French clinicians think “milnacipran constitutes an important new treatment option in major depression” following a multi-center double-blind, randomised trial among 109 patients.
It was led by clinicians at Centre Hospitalier Intercommunal Poissy St-Germain-En-Laye, Centre Hospitalier Emile Roux, Eaubonne, and Clinical Institut de Recherche Pierre Fabre, Boulogne, France.
They compared the efficacy and tolerance of milnacipran, a novel selective serotonin and noradrenaline reuptake inhibitor, with mipramine. All of the patients had a major depression as measured by two established ratting scales. They underwent a three to seven day washout before treatment began over a two-week period in hospital.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!